EPI-7386 Combo Therapies Enter Trial for Certain mCRPC Patients

EPI-7386 Combo Therapies Enter Trial for Certain mCRPC Patients

284201

EPI-7386 Combo Therapies Enter Trial for Certain mCRPC Patients

Essa Pharma has entered a clinical collaboration with Janssen to evaluate its small molecule inhibitor EPI-7386, in combination with either Erleada (apalutamide) or Zytiga (abiraterone acetate) plus prednisone, for patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the agreement, Janssen will conduct up to two Phase 1/2 clinical trials evaluating these combinations in people who failed second-generation androgen receptor inhibitors such as Erleada or Zytiga. A joint committee from both companies will oversee…

You must be logged in to read/download the full post.